Cancer-associated retinopathy after anti-programmed death 1 (PD-1) antibody for treating hepatocellular carcinoma——a case report of a Chinese patient

Chen, Qian; Feng, Chaoyi; Sun, Chuan-bin; Wang, Min; Chen, Ling; Sun, Xinghuai; Tian, Guohong

doi:10.1016/j.ajoc.2022.101370

Cited by 8 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five CAR cases have been described: 2 with nivolumab, 1 with atezolizumab, 1 with pembrolizumab and one with the combination of nivolumab and ipilimumab [16][17][18][19][20]. There was an equal male-female ratio and the mean age was 62 years (range 52 -75 years, 1 case age and gender NS).…”

Section: Carmentioning

confidence: 99%

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature

Casselman

Jacob

Schauwvlieghe

2023

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

Purpose To describe different ocular paraneoplastic syndromes in patients treated with Immune Checkpoint Inhibitors (ICI), its relation with different types of ICI and different types of tumors, and its implications for treatment. Methods A comprehensive review of the literature was performed. Results Patients treated with ICI can present with different ocular paraneoplastic syndromes, such as Carcinoma Associated Retinopathy (CAR), Melanoma Associated Retinopathy (MAR) and paraneoplastic Acute Exudative Polymorphous Vitelliform Maculopathy (pAEPVM). In literature, the different types of paraneoplastic retinopathy are mostly related to different types of primary tumors, with MAR and pAEPVM seen in melanoma, and CAR in carcinoma. Visual prognosis is limited in MAR and CAR. Conclusion Paraneoplastic disorders result from an antitumor immune response against a shared autoantigen between the tumor and ocular tissue. ICI enhance the antitumor immune response, which can lead to increased cross-reaction against ocular structures and unmasking of a predisposed paraneoplastic syndrome. Different types of primary tumors are related to different cross-reactive antibodies. Therefore, the different types of paraneoplastic syndromes are related to different types of primary tumors and are probably unrelated to the type of ICI. ICI-related paraneoplastic syndromes often lead to an ethical dilemma. Continuation of ICI treatment can lead to irreversible visual loss in MAR and CAR. In these cases overall survival must be weighed against quality of life. In pAEPVM however, the vitelliform lesions can disappear with tumor control, which may involve continuation of ICI.

show abstract

Section: Carmentioning

confidence: 99%

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature

Casselman

Jacob

Schauwvlieghe

2023

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

show abstract

“…The results have been mixed in terms of short-term outcomes. 71,81-105 Since 2012, there have been 40 cases reported with extractable information (Table, supplement). Among those patients, 25 (62.5%) had more than 3 months of follow-up.…”

Section: Cancer-associated Retinopathymentioning

confidence: 99%

“…86,99,101 Several reports have appeared in 2022 describing considerable worsening or rapid progression of immune-mediated retinopathy after initiation of immunemodulating therapy. [102][103][104][105] These apparent visual complications of therapy either mimic CAR or are a distinct complication of immune-modulating therapy. Still, others have reported benefit from treatment with intravitreal corticosteroids administered by injection or slow-release insert.…”

Section: Therapymentioning

confidence: 99%

Ocular Paraneoplastic Syndromes: A Critical Review of Diffuse Uveal Melanocytic Proliferation and Autoimmune Retinopathy

et al. 2022

View full text Add to dashboard Cite

Background: Dozens of paraneoplastic syndromes affect the visual system ranging from conjunctival pemphigoid to encephalopathy of the occipital cortex. The most profiled ocular syndromes are bilateral diffuse uveal melanocytic proliferation (BDUMP) and the autoimmune retinopathies. Purpose: To review the critical features of these 2 entities then concentrate on advancements in treatment made within the last 10 years. Study Design: Literature review with structured data abstraction. Results: Major insights into pathogenesis have been wanting. Plasmapheresis appears to improve vision in a substantial proportion of patients with BDUMP. The number of clinical variables that influence visual outcome in paraneoplastic retinopathies combined with the variety of local and systemic treatment options makes interpretation of clinical effectiveness difficult. Conclusions: The rarity of these disorders makes randomized clinical trials unlikely. It may be time for a clinical professional organization to use a modified Delphi method to establish a consensus algorithm for the diagnosis and management of retinal paraneoplastic syndromes to augment clinical communications and clinical trials.

show abstract

Nivolumab

2022

Reactions Weekly

View full text Add to dashboard Cite

Cancer-associated retinopathy after anti-programmed death 1 (PD-1) antibody for treating hepatocellular carcinoma——a case report of a Chinese patient

Cited by 8 publications

References 11 publications

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature

Ocular Paraneoplastic Syndromes: A Critical Review of Diffuse Uveal Melanocytic Proliferation and Autoimmune Retinopathy

Nivolumab

Contact Info

Product

Resources

About